[Cytokines in the clinic].
Recombinant cytokines are available for clinical evaluation since several years. They are expected to have novel effects with fewer side effects than conventional cytostatics. Until now interferon alpha has been registered for Kaposi's sarcoma and hairy cell leukemia. Further indications will follow. Hemopoietic growth factors will have a major impact, as no doubt exists about their effectiveness, but their indications need to be defined more thoroughly. Many substances like interleukin 2, tumor necrosis factor and interleukin 1 are currently at a purely experimental stage.
Obrist
R
R
Departement Innere Medizin, Universität, Kantonsspital Basel.
D001685:Biological Factors / Q000627:therapeutic use*; D016207:Cytokines; D006801:Humans; D007938:Leukemia / Q000628:therapy*; D009369:Neoplasms / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use
D001685:Biological Factors; D016207:Cytokines; D011994:Recombinant Proteins
Zytokine in der Klinik.